IL21120033 / Ildong - LARVOL DELTA

Ildong Pharmaceutical accelerates drug development for metabolic, autoimmune diseases (Chosun Biz) - "In the same month, Irydbms participated in the European League Against Rheumatism (EULAR) conference in Barcelona, Spain, and disclosed preclinical research results related to the autoimmune disease drug candidate 'IL21120033.' The results from experiments conducted on animals with rheumatoid arthritis showed excellent outcomes....Additionally, in some high-dose groups of IL21120033, a phenomenon of cartilage regeneration to normal levels was also observed, and the company stated that it demonstrated superior efficacy in inflammation suppression and cartilage protection compared to the comparative drug upadacitinib."

Preclinical • Rheumatoid Arthritis

Efficacy of a Novel CXCR7 Agonist In Collagen-Induced Arthritis (CIA) Mouse Model. (EULAR 2025) - " In the collagen II induced arthritis (CIA) model, the male DBA/1 mice were divided into 5 groups: sham, model vehicle group, IL21120033 (30 and 60 mg/kg), ABT494 as positive control group. IL21120033 demonstrated strong anti-rheumatoid arthritis (RA) efficacy by reducing CXCL12 levels and subsequently inhibiting CXCR4⁺ T cell migration into the joints of CIA mice. These findings identify IL21120033 as the first CXCR7 agonist to show significant efficacy in an animal model of rheumatoid arthritis."

Preclinical • Anesthesia • Immunology • Inflammatory Arthritis • Pain • Rheumatoid Arthritis • Rheumatology • ACKR3 • CXCL12 • CXCR4